Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 260

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 260
---
</div>

Unless otherwise stated, all references to “DiamiR,” and similar designations in this section refer to DiamiR Biosciences Corp, a Delaware corporation, and its wholly-owned subsidiary DiamiR, LLC a private Delaware limited liability company.

Overview

DiamiR Biosciences Corp.
(“DiamiR”) is a molecular diagnostic company focused on developing minimally invasive tests for early detection and monitoring
of Mild Cognitive Impairment, Alzheimer’s, Parkinson’s, other neurodegenerative diseases, and cancer. The proprietary technology
developed at DiamiR is based on quantitative analysis of circulating organ-enriched microRNAs in plasma. Short-term objectives of DiamiR
include the development of Lab-Developed tests (LDTs) under CLIA guidelines based on the identified miRNA expression signatures. The tests
will be used for screening, patient stratification, as well as disease and treatment monitoring.

DiamiR was incorporated in
Delaware on June 16, 2014, and primarily operates through its wholly-owned subsidiary, DiamiR, LLC, which was incorporated as a limited
liability company in Delaware on September 17, 2009. In October 2014, DiamiR entered into a Share Exchange Agreement with DiamiR,
LLC, pursuant to which DiamiR acquired 100% of the issued and outstanding units of DiamiR, LLC in exchange for 4,282,000 shares (100%)
of DiamiR’s common stock (the “Share Exchange”), and DiamiR, LLC became a wholly-owned subsidiary of DiamiR. The
Share Exchange was recognized as a combination of entities under common control as both DiamiR, LLC and DiamiR have been controlled before
and after the transaction by the same shareholders.

In July 2025, the Company
entered into a definitive merger agreement with Aptorum Group Limited, a publicly traded Cayman Islands company (“Aptorum”).
Pursuant to the merger agreement, if completed, shareholders of the Company would receive shares of the surviving company’s common
stock in a share exchange. Under the merger agreement, the Company’s outstanding convertible notes are expected to be converted
to shares of the surviving company’s common stock. Concurrent with the execution of the merger agreement, the companies entered
into a management service agreement and a license agreement through earlier of the closing of the merger or December 31, 2025, under
which the Company will provide